Korea Investment CORP Sells 33,899 Shares of AbbVie Inc. $ABBV

Korea Investment CORP lessened its position in AbbVie Inc. (NYSE:ABBV) by 2.2% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,516,251 shares of the company’s stock after selling 33,899 shares during the period. AbbVie comprises about 0.7% of Korea Investment CORP’s investment portfolio, making the stock its 19th biggest holding. Korea Investment CORP’s holdings in AbbVie were worth $346,448,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Sumitomo Life Insurance Co. lifted its position in AbbVie by 25.7% during the fourth quarter. Sumitomo Life Insurance Co. now owns 19,314 shares of the company’s stock valued at $4,413,000 after purchasing an additional 3,954 shares during the period. Wealthspire Advisors LLC raised its position in AbbVie by 16.0% in the fourth quarter. Wealthspire Advisors LLC now owns 58,434 shares of the company’s stock worth $13,352,000 after acquiring an additional 8,053 shares during the period. Tillman Hartley LLC raised its position in AbbVie by 3.6% in the fourth quarter. Tillman Hartley LLC now owns 3,496 shares of the company’s stock worth $799,000 after acquiring an additional 121 shares during the period. Allianz SE increased its stake in shares of AbbVie by 2.7% in the fourth quarter. Allianz SE now owns 97,245 shares of the company’s stock worth $22,220,000 after purchasing an additional 2,596 shares in the last quarter. Finally, Macquarie Group Ltd. increased its stake in shares of AbbVie by 5.5% in the fourth quarter. Macquarie Group Ltd. now owns 986,044 shares of the company’s stock worth $224,893,000 after purchasing an additional 51,559 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
• Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
• Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on ABBV shares. Royal Bank Of Canada started coverage on shares of AbbVie in a research note on Tuesday, February 24th. They set an “outperform” rating and a $260.00 target price for the company. Canaccord Genuity Group increased their price objective on shares of AbbVie from $262.00 to $265.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Evercore set a $235.00 price objective on shares of AbbVie in a research report on Friday, May 15th. Piper Sandler increased their price objective on shares of AbbVie from $294.00 to $298.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Finally, Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, June 7th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $253.43.

AbbVie Price Performance

Shares of ABBV opened at $227.54 on Friday. AbbVie Inc. has a 1-year low of $181.73 and a 1-year high of $244.81. The company has a 50-day moving average of $211.05 and a 200 day moving average of $219.07. The firm has a market capitalization of $402.02 billion, a price-to-earnings ratio of 112.09, a PEG ratio of 0.69 and a beta of 0.32.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same quarter last year, the business posted $2.46 EPS. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. On average, equities analysts anticipate that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.